bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of “Hold” from Brokerages

bluebird bio, Inc. (NASDAQ:BLUE) has been given a consensus rating of “Hold” by the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $5.87.

Several equities research analysts have weighed in on BLUE shares. Wells Fargo & Company dropped their price objective on bluebird bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, March 27th. HSBC lowered their target price on bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research note on Tuesday, March 5th. Wedbush lowered their target price on bluebird bio from $1.72 to $1.68 and set a “neutral” rating for the company in a research note on Tuesday, March 19th. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 target price on shares of bluebird bio in a research note on Wednesday, March 27th. Finally, William Blair restated a “market perform” rating on shares of bluebird bio in a research note on Tuesday, January 9th.

bluebird bio Stock Performance

NASDAQ BLUE opened at $0.95 on Tuesday. bluebird bio has a fifty-two week low of $0.88 and a fifty-two week high of $5.53. The stock has a 50 day simple moving average of $1.26 and a two-hundred day simple moving average of $2.02. The stock has a market cap of $104.27 million, a P/E ratio of -1.29 and a beta of 0.74.

Institutional Trading of bluebird bio

A number of institutional investors and hedge funds have recently modified their holdings of BLUE. Aigen Investment Management LP bought a new stake in shares of bluebird bio in the 3rd quarter worth $34,000. Sequoia Financial Advisors LLC bought a new stake in shares of bluebird bio in the 4th quarter worth $37,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of bluebird bio in the 4th quarter worth $37,000. Johnson Investment Counsel Inc. increased its holdings in shares of bluebird bio by 111.1% in the 4th quarter. Johnson Investment Counsel Inc. now owns 27,889 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 14,680 shares in the last quarter. Finally, Enterprise Bank & Trust Co bought a new stake in shares of bluebird bio in the 1st quarter worth $38,000. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.